N/A N=32 Developing Objective Measures of Levodopa Induced Dyskinesia: (Study 1)
Dyskinesias · Movement Disorders · Parkinson Disease
Primary: Gaitmat Stance Measurements (AUC) — 4.48; 10.8; 20.9; 2.8 Root Mean Square of Velocity*Minutes
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=298 Addressing Involuntary Movements in Tardive Dyskinesia
Tardive Dyskinesia
Primary: Change in Total Motor Abnormal Involuntary Movement Scale (AIMS) Score From Baseline to Week 12 Using a Mixed Model For Repeated Measures (MMRM) — -1.4; -2.1; -3.2; -3.3…
Phase 2 N=75 Efficacy and Tolerability of IRL790 in Parkinson's Disease Dyskinesia
Parkinson Disease
Primary: Unified Dyskinesia Rating Scale (UDysRS) — -4.2; -7.0 score on a scale
Phase 3 N=117 Aim to Reduce Movements in Tardive Dyskinesia
Tardive Dyskinesia
Primary: Change in Centrally Read Abnormal Involuntary Movement Scale (AIMS) Score From Baseline to Week 12 Using Mixed Model Repeated Measures (MMRM) Analysis — -3.0; -1.6 units…
N/A N=80 Preventing Levodopa Induced Dyskinesia in Parkinson's Disease With HMG-CoA Reductase Inhibitors
Parkinson Disease · Dyskinesia, Drug-Induced
Primary: Peak Unified Dyskinesia Rating Score (UDysRS) — 10.9; 10.8; 13.2 score on a scale — p=0.63
Phase 2 N=253 Dyskinesia in Parkinson's Disease (Study P04501)
Parkinson Disease · Movement Disorders · Central Nervous System Diseases
Primary: Change From Baseline to Endpoint of 12 Weeks in the 3-day Average of Awake Time Per Day Spent in the "Off" State — -0.4; -1.3; -1.6; -1.7 hours/day — p=0.753
Phase 3 N=337 Reducing Involuntary Movements in Participants With Tardive Dyskinesia
Tardive Dyskinesia
Primary: Part A, B, and C: Number of Participants With Treatment-Emergent AEs (TEAEs), Serious TEAEs, Severe TEAEs, Drug-Related TEAEs, and TEAEs Leading to Withdrawal — 269; 23…
Phase 3 N=63 A Study of TEV-50717 (Deutetrabenazine) for the Treatment of Dyskinesia in Cerebral Palsy in Children and Adolescents
Cerebral Palsy, Dyskinetic
Primary: Change From Baseline in the Movement Disorder-Childhood Rating Scale (MD-CRS) Part II Total Score (Movement Disorder Severity, Centrally Read) at Week 15 — -0.4; -1.5…
Phase 3 N=506 Sarizotan HC1 in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia
Parkinson's Disease · Dyskinesia
Primary: Responder Rate Based on Unified Parkinson's Disease Rating Scale (UPDRS) Items 32 and 33 at Week 12 — 30.4; 33.2 percentage of subjects
Phase 1 N=30 Reducing Dyskinesia in Parkinson's Disease With Omega-3 Fatty Acids
Parkinson's Disease
Primary: Efficacy of DHA - Change in Blood ng/dL Levels — 102.18; -13.20 ng/dL - Blood
Phase 4 N=68 Validation of Dyskinesia Rating Scales
Parkinson's Disease
Primary: The Investigators Will Assess Effect Size With Each Scale for Detecting Change From Baseline and Change Between Amantadine and Placebo; Allowing Assessment of…
Phase 2 N=14 Safety and Efficacy of AVP-923 in the Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease Patients
Dyskinesia · Parkinson's Disease
Primary: Least Squares Mean Dyskinesia Severity Area Under the Curve (AUC) Score As Assessed By Modified Movement Disorder Society-Unified Dyskinesia Rating Scale (MDS-UDysRS)…
N/A N=38 Unlocking Dystonia From Parkinson's Disease With Directional DBS Technology
Dystonia-Parkinsonism, Adult-Onset · Parkinson Disease
Primary: Burke-Fahn-Marsden Dystonia Rating Scale — 3.5 units on a scale — p=<0.001
Phase 3 N=398 Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
Parkinson's Disease · Dyskinesia
Primary: Change From Baseline in Diary-Based On-Time Without Dyskinesia at Week 12 — 1.6; 1.9; 1.7; 1.8 hours/day
Phase 2 N=109 NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
Tardive Dyskinesia
Primary: Abnormal Involuntary Movement Scale (AIMS) Dyskinesia Total Score Change From Baseline at Week 6 — -2.5; -3.3 units on a scale — p=0.2966
Phase 2 N=155 A Clinical Study of Mesdopetam in Patients With Parkinson's Disease Experiencing Levodopa Induced Dyskinesia
Parkinson Disease
Primary: Change in Average Daily Hours of ON-time Without Troublesome Dyskinesia With Mesdopetam Compared to Placebo as Assessed With 24-hour Patient Home Diaries From Baseline…
Phase 3 N=61 A Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects With Advanced Parkinson's Disease (DYSCOVER)
Parkinson's Disease (PD)
Primary: Mean Change From Baseline to Week 12 in Unified Dyskinesia Rating Scale (UDysRS) Total Score — -2.33; -17.37 units on a scale — p=<0.0001
Phase 3 N=234 A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
Tardive Dyskinesia
Primary: Abnormal Involuntary Movement Scale (AIMS) Dyskinesia Total Score Change From Baseline at Week 6 — -0.1; -3.2; -1.9 scores on a scale — p=<0.0001
Phase 3 N=83 Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED Study)
Dyskinesia · Levodopa Induced Dyskinesia · Parkinson's Disease
Primary: Change in the Unified Dyskinesia Rating Scale (UDysRS) Total Score From Baseline to Week 8 — -6.7; -12.3; -17.9; -16.7 units on a scale — p=0.0051
Phase 3 N=77 Efficacy and Safety Study of ADS-5102 in PD Patients With Levodopa-Induced Dyskinesia
Dyskinesia · Levodopa-Induced Dyskinesia (LID) · Parkinson's Disease (PD)
Primary: Change in the Unified Dyskinesia Rating Scale (UDysRS) Total Score — -6.3; -20.7 units on a scale — p=<0.0001
N/A N=9 Chronic Effects of DBS in Parkinson's Disease and Dystonia
Parkinson's Disease · Isolated Dystonia
Primary: Number of Patients With Parkinson's Disease With Reliable Cortical and Sub-cortical Brain Signals — 5 Participants
Phase 3 N=256 Efficacy and Safety of MT-5199 in Subjects With Tardive Dyskinesia
Tardive Dyskinesia
Primary: Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Total Score (Central Assessment) at Week 6 — -0.1; -2.3; -3.7 units on a scale — p=<0.001
Phase 2 N=6 Risperidone for the Treatment of Huntington's Disease Involuntary Movements
Huntington Disease · Chorea
Primary: Change From Baseline in Mean Unified Huntington's Disease (HD) Rating Scale Total Maximal Chorea (UHDRS TMC) Score — -2.4 score on a scale — p=0.27
Phase 2 N=37 NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Tardive Dyskinesia
Primary: Abnormal Involuntary Movement Scale (AIMS) Dyskinesia Total Score — 9.9; 9.1; 8.8 units on a scale — p=0.5880
Phase 2 N=102 NBI-98854 Dose Titration Study for the Treatment of Tardive Dyskinesia
Tardive Dyskinesia
Primary: Abnormal Involuntary Movement Scale (AIMS) Dyskinesia Total Score Change From Baseline at Week 6 — -0.3; -3.4 units on a scale — p=<.0001
Phase 1 N=12 Acute Effects of Preladenant (SCH 420814) on Dyskinesia and Parkinsonism in Levodopa Treated Participants (P05550)
Parkinson Disease
Primary: Mean Peak Dyskinesia Score — 11.00; 11.42; 8.50 Score on a scale
Phase 2 N=34 Study in Advanced Parkinson's Disease Patients With Predictable Motor Fluctuations
Parkinson's Disease · Motor Fluctuations
Primary: The Primary Objective of This Study is to Explore the Efficacy and Tolerability of DM-1992 Compared to a Standard CD/LD IR Formulation as Measured by Percent "OFF" Time…
Phase 3 N=126 ADS-5102 for the Treatment of Levodopa Induced Dyskinesia (EASE LID Study)
Dyskinesia · Levodopa Induced Dyskinesia (LID) · Parkinson's Disease
Primary: Change From Baseline in the Unified Dyskinesia Rating Scale (UDysRS) Score at Week 12 — -8.0; -15.9 units on a scale — p=0.0009
N/A N=5 Thalamic Deep Brain Stimulation for Secondary Dystonia in Children and Young Adults
Dystonia
Primary: Change From Baseline in Burke-Fahn-Marsden Dystonia Rating Scale — 14.7 change in points on a scale
Phase 3 N=12 Effect of Dysport Injections on Energy Expenditure and Walking Efficiency in Children With Cerebral Palsy
Cerebral Palsy
Primary: Oxygen Consumption (ml/kg/Min) — 14.82; 16.75; 28.77 ml/kg/min